"Wegovy: The Surging Trend in Youth Weight-Loss Medication Use"

The use of Novo Nordisk's weight-loss drug Wegovy among U.S. adolescents has sharply risen, with 1,268 children aged 12 to 17 starting treatment in the first 10 months of 2023, compared to only 25 in 2022. This increase reflects a growing willingness among families to embrace the drug as a powerful tool to address record rates of pediatric obesity, despite concerns about long-term risks and benefits. While the overall numbers remain small in comparison to the prevalence of obesity among U.S. children, the data indicate a shift towards utilizing highly effective treatments like Wegovy, with some families reporting significant weight loss and improved quality of life for their children.